

## IL6

### Research Grade Olokizumab

<b>Catalog No.</b>	DHC15804A DHC15804B	<b>Quantity:</b>	100 µg 1.0 mg
<b>Alternate Names:</b>	Interleukin-6, B-cell stimulatory factor 2, BSF-2, CTL differentiation factor, CDF, Hybridoma growth factor, Interferon beta-2, IFN-beta-2		
<b>Description:</b>	Olokizumab is a clinical stage anti-IL-6 monoclonal antibody, that was designed for potential to treat autoimmune diseases. The antibody blocks assembly of the hexameric IL-6/IL-6 $\alpha$ -receptor/gp130 (IL6ST) complex that is required for signal transduction.		
<b>UniProt ID (target):</b>	P05231		
<b>Specificity:</b>	Human IL-6		
<b>Source:</b>	XtenCHO cell line		
<b>Isotype:</b>	Humanized IgG4-kappa		
<b>INN:</b>	Olokizumab		
<b>Concentration:</b>	1.0 mg/ml, lot specific		
<b>Formulation:</b>	0.01M PBS, pH 7.4.		
<b>Purity:</b>	> 95% as determined by SDS-PAGE		
<b>Purification:</b>	Protein A/G affinity chromatography		
<b>Endotoxin:</b>	$\leq 0.01$ EU/ $\mu$ g by LAL analysis		
<b>Storage &amp; Stability:</b>	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. <b>Avoid freeze/thaw cycles.</b>		

**NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.**